Monthly Oncology Tumor Boards: Management of Well-Differentiated Grade 3 Neuroendocrine Tumors
It is important to inform clinicians about this new section of the NCCN Guidelines for Neuroendocrine and Adrenal Tumors, which include recommendations for the evaluation, management, and surveillance of well-differentiated G3 NETs. Keeping clinicians abreast of updated treatment options may help improve clinical decision-making to better address patients’ medical needs.
Monthly Oncology Tumor Boards: Management of Non-Metastatic Prostate Cancer
Clinicians need to be knowledgeable about newer tools that can improve risk stratification, and they need to understand when these tools have the possibility to change management so that unnecessary testing can be avoided. In addition, clinicians should be educated about the heterogeneity among risk groups, so that nuanced discussions with patients can inform decisions surrounding active surveillance.
2022-2023 Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a set of step-by step evidence-based, consensus-driven recommendations to ensure that patients receive preventive, diagnostic, treatment, and supportive services that are most likely to lead to optimal outcomes.

NCCN Pharmacy Updates: The Role of Tyrosine Kinase Inhibitors in Pediatric Acute Lymphoblastic Leukemia
It is important for health care professionals caring for pediatric patients with ALL to recognize aspects of optimal dosing and frequency, appropriate use in particular genomic alterations, mechanisms of resistance, and patient-specific counseling points to ensure efficacy and compliance of TKIs.
NCCN Pharmacy Updates: Navigating Advances in Targeted Therapies for Advanced Esophageal, Esophagogastric Junction (EGJ) and Gastric Cancers
The standards of care in the first-line setting for the treatment of advanced or metastatic esophageal, esophagogastric junction and gastric cancer are evolving rapidly. There is a need to review the current landscape of treatment regimens and understand how to incorporate the new standards of care to effectively treat this patient population.
NCCN 2022 Nursing Program: Advancing Oncology Nursing

This program provides oncology nurses with comprehensive and clinically relevant information to optimize clinical care and patient education.

NCCN 2022 Annual Conference

The NCCN 2022 Annual Conference is designed to fill real and important medical educational needs of cancer care providers to improve and facilitate quality, effective, efficient and accessible cancer care so patients can live better lives.

Monthly Oncology Tumor Boards: Multidisciplinary Management of Localized Rectal Cancer
Trimodal therapy approaches for localized rectal cancer continue to evolve as new data helps define how to best improve outcomes while reducing adverse effects, with total neoadjuvant therapy among the approaches of recent interest. Clinicians can benefit from education on relevant clinical trial results related to trimodal therapy for localized rectal cancer and guidance on how these data may be best applied to clinical practice.
NCCN Pharmacy Updates: Updates in the Management of Unresectable or Metastatic Cutaneous Melanoma
Pharmacists play a critical role in patient education, monitoring, and management of treatment-related toxicities and will benefit from a comprehensive review of the novel treatments for cutaneous melanoma.
Monthly Oncology Tumor Boards: New Targeted Therapies for Non-Small Cell Lung Cancer
This tumor board will discuss how to select the most appropriate therapy for patients with non-small cell lung cancer (NSCLC) using a case-based format. New targeted therapy regimens are being rapidly approved for patients with metastatic NSCLC and have been shown to improve outcomes for these patients.

Pages

Subscribe to RSS - Live Webinar